

Title:

**Current Trends in Regenerative Liver Surgery:
Novel Clinical Strategies and Experimental Approaches**

Short title:

Trends in Regenerative Liver Surgery

Authors:

Jan Heil^{1,2}, [Marc Schiesser^{3,4}](#), Erik Schadde^{1,3,4,5}

¹ Institute of Physiology, University of Zurich, Zurich, Switzerland

² Department of General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt, Germany

³ Chirurgisches Zentrum Zürich (CZZ), Klinik Hirslanden Zurich, Zurich, Switzerland

⁴ Chirurgie Zentrum Zentralschweiz (CZZ) Hirslanden St. Anna, Lucerne, Switzerland

⁵ Department of Surgery, Rush University Medical Center Chicago, IL, USA

Correspondance:

Erik Schadde, MD FACS FEBS (HPB)

Institute of Physiology

University of Zurich

Winterthurerstr. 190

CH-8057 Zurich

Switzerland

Phone: +41 79 418 24 45

Email: erik.schadde@icloud.com

Length of the manuscript

Abstract: [336 words](#)

Manuscript (excluding abstract): [9054 words](#)

Grant Support:

There was no specific financial support for the performance of this study.

Disclosures:

No disclosures of potential conflicts (financial, professional or personal) relevant to the manuscript.

List of Abbreviations:

ALPPS - associating liver partition and portal vein ligation for staged hepatectomy

AVP - Vascular Amplatzer Plugs

CCC - cholangiocellular carcinoma

CI - confidence interval

CRC - colorectal cancer

CLRM	- colorectal liver metastasis
CT	- computed tomography
eLVD	- extended liver venous deprivation
FLR	- future liver remnant
hALLPS	- hybrid associating liver partition and portal vein ligation for staged
hepatectomy	
HBS	- hepatobiliary scintigraphy
HCC	- hepatocellular carcinoma
HVE	- hepatic vein embolization
ISGLS	- International Study Group of Liver Surgery
IHCC	- intrahepatic cholangiocellular carcinoma
IL-6	- interleukine-6
IQR	- interquartile range
KGR	- kinetic growth rate
lap-ALPPS	- laparoscopic-associating liver partition and portal vein ligation for
staged	
LVD	- liver venous deprivation
MRI	- magnetic resonance imaging
NBCA/lipiodol	- n-butyl-cyanoacrylate and iodized oil
NET	- neuroendocrine tumour
p-ALLPS	- partial-associating liver partition and portal vein ligation for staged
hepatectomy	
PHCC	- perihilar cholangiocarcinoma
PHLF	- post-hepatectomy liver failure
PVE	- portal vein embolization
PVE/HVE	- simultaneous portal and hepatic vein embolization
PVL	- portal vein ligation
RALPPS	- associating liver partition with portal vein ligation for staged
hepatectomy assisted with radiofrequency	
RASPE	- radiological simultaneous porto-hepatic vein embolization
REBITH trial	- rapid induction of liver regeneration for major hepatectomy trial
RCT	- randomized controlled trial
sFLR	- standardized future liver remnant
T-ALPPS	- tourniquet- associating liver partition and portal vein ligation for
staged hepatectomy	
TNF- α	- tumour necrosis factor alpha
TP-ALPPS	- tourniquet partial- associating liver partition and portal vein ligation
for staged hepatectomy	
SD	- standard deviation

Abstract

Liver resections are performed to cure patients with hepatobiliary malignancies and metastases to the liver. However, only a small proportion of patients is resectable, largely because only up to be 70% of liver tissue is expendable in a resection. If larger resections are performed, there is a risk of posthepatectomy liver failure. Regenerative liver surgery addresses this limitation by increasing the future liver remnant to an appropriate size before resection. Since the 1980ies, it has evolved from portal vein embolization (PVE) to a multiplicity of methods. This review presents an overview over the available methods and their weaknesses and strength.

The first use of PVE was in patients with large hepatocellular carcinomas. The increase of liver volume induced by PVE equals that of portal vein ligation, but both result only in a moderate volume increase. While awaiting sufficient liver growth, 20-40% of patients fail to achieve resection, mostly due to progression of disease. The MD Anderson Cancer Centre group improved the PVE methodology by adding segment 4 embolization (“high-quality PVE”) and demonstrated that oncological results were better than non-surgical approaches in this previously unresectable patient population. In 2012, a novel method of liver regeneration was proposed and called Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS). ALPPS accelerated liver regeneration by a factor of 2-3 and increased the resection rate to 95-100%. However, ALPPS fell short of expectations due to a high mortality and a limited utility only in highly selected patients. Accelerated liver regeneration, however, was there to stay. This is evident in the multiplicity of ALPPS modifications like radiofrequency- or partial-ALPPS. Overall, rapid liver regeneration allowed an expansion of resectability with increased perioperative risk. A standardized low risk approach to rapid hypertrophy has been missing and the techniques used depend on local expertise and preference. Recently, however, simultaneous portal and hepatic vein embolization (PVE/HVE), appears to offer both, rapid hypertrophy and no increased clinical risk. While prospective randomized comparisons are underway, PVE/HVE has the potential to become the future gold standard.

Key words: regenerative liver surgery, future liver remnant, portal vein embolization, ALPPS, liver venous deprivation, simultaneous portal and hepatic vein embolization, resectability

1. Introduction.

The most common hepatic tumours are liver metastases from colorectal cancer (CRC), [1] which is the third most frequent cancer worldwide. [2] About 50% of patients with CRC develop colorectal liver metastases (CRLM). [2, 3] In comparison primary hepatobiliary tumours are less prevalent and hepatocellular carcinoma (HCC) accounts for 80% of them. HCC is the third most common cause for cancer-related mortality worldwide. [2] While liver resection may cure patients with liver tumours, most patients are unresectable. [4, 5]

When resectability is assessed, a risk-benefit analysis has to be performed. The amount of liver directly impacts the risk for the patient. The Sloan-Kettering group showed in a landmark paper [6] that the number of resected liver segments correlates with postoperative morbidity and mortality. Besides blood loss, the number of resected liver segment was shown to be the main predictor for postoperative morbidity and mortality, more so than the complexity of the procedure itself (bile duct reconstruction, etc.). With increased usage of preoperative computed tomography (CT) and magnetic resonance imaging (MRI) in the 1990ies, the analysis shifted from the liver *segments resected* to the planned *liver volume left behind*, [7] and from the risk assessment endpoint *complications and mortality* to *posthepatectomy liver failure* (PHLF). PHLF is to be absolutely avoided in liver resection. For a more accurate estimation of the amount of liver volume left behind, the MD Anderson group introduced the concept of standardized future liver volume (sFLR), i.e. the ratio of the manually measured future liver remnant (FLR) volume to the estimated total liver volume based on biometric formulas. [8] Established in meticulous retrospective studies, a minimal sFLR of 25% in healthy livers up to 30% in patients with damaged livers (steatosis and chemotherapy damaged livers) became the universally accepted cut-off for relatively safe liver surgery, a substantial progress in the field. [7, 9-11] Cut-offs for cirrhosis remain controversial.

In patients with a too small sFLR at risk of PHLF, various interventions can be performed that allow an increase of the volume of the sFLR to a larger size prior to resection. [12] This article gives an overview over the development and currently utilized strategies in regenerative liver surgery in face of an increasingly older and comorbid patient population with metastatic liver disease that under no circumstances can be exposed to the risk of PHLF.

2. Historical development of regenerative liver surgery

All procedures used to increase liver volume prior to resection make use of the same principle: re-rerouting of portal vein blood to the small future liver [12]. Interestingly, this

method was already described 100 years ago in an experimental rabbit model by Peyton Rous the Nobel recipient for his work on oncogenic viruses. [13] Rous observed in rabbits that the occlusion of the portal branches of a hemiliver results in an atrophy of the occluded main liver and a compensatory hypertrophy of the non-occluded caudate lobe. Sixty years later, Japanese surgeons applied this principle to humans by performing transcatheter interventional embolization of the portal vein to patients with HCC and called it portal vein embolization (PVE). [14] While PVE was increasingly used in all types of liver tumours including metastases [15], a novel concept to reduce the risk of PHLF after the resection of bilobar liver metastasis was introduced by the Paul-Brousse group in 1999 where the resection was performed in two distinct stages and called *two-stage hepatectomy* (TSH). [16]

These two major innovations of the 1990ies, PVE and TSH, soon spawned a variety of procedures to improve the surgical treatment of patients with metastatic disease. A foundational review categorizes them into four types: [17] (1) The *right first approach* as pioneered by Adam et al. in 2000, [16] where mostly the main tumour mass is resected during the first stage. PVE can then be performed if necessary (only 6 of 16 patients in the initial series needed it) and the 2nd stage is not performed until several months later (median of 4 month (range 2-14)) in the initial series in order to give the patient and the liver time to recover. (2) The *left first approach* pioneered by the Beaujon group [18], where the left hemiliver is cleaned of tumour in parenchymal sparing resections followed by a right-sided PVL (in all patients in the initial series) followed rather rapidly by a right or extended right hepatectomy (after a median of 6 weeks, range 4-8). (3) The *left first approach* [19] with PVE between stages was pioneered by the Strasbourg group. Both, PVE and PVL, appear to be equivalent in terms of liver growth [20] and have increasingly been used in metastasis to the liver and hepatobiliary malignancies in the last decades. [21] While PVL cannot be improved much, PVE has been modified by the MD Anderson group to include segment 4 embolization (“high-quality PVE) in patients with the need of an extended right hepatectomy. [22] Also, the prospective randomized “BestFLR” trial showed the superiority of n-butyl-cyanoacrylate to other embolic agents in terms of liver growth. [23]

~~The concept of TSH with the addition of regenerative manoeuvres became well-accepted in the treatment for liver metastases in a variety of important retrospective analyses demonstrating superior outcomes in borderline resectable patients. [24, 25] Nevertheless, liver volume gain induced by PVE/PVL remained limited and high dropout rates up to 30-43% while awaiting sufficient liver growth remained the Achilles tendon of regenerative liver surgery throughout the 2000 years. [20, 26, 27]~~

(4) The *in-situ-split hepatectomy* technique was introduced in 2012 by the Regensburg group [28] to accelerate liver growth between stages by performing an additional transection of the liver parenchyma in addition to PVL. Investigations into the physiological mechanisms in animals revealed that the transection inhibits the formation of portal vein collaterals between the portalized and deportalized liver lobe, which decreases the portal hyperflow to the FLR and the steal of hepatotrophic factors from the growing FLR. [29]

Additionally, to these to these 4 regenerative procedures, a fifth variant was introduced in 2016, when the Montpellier group proposed the liver venous deprivation technique (LVD) by abrogating portal venous collaterals by adding a hepatic vein occlusion to PVE in a single interventional procedure. [30] This procedure was later simplified as “PVE/HVE” or double embolization.

3. *The new paradigm of rapid hypertrophy - ALPPS*

Rerouting of portal vein flow induces liver volume growth but not to the same extent as the rapid regenerative growth after major hepatectomy. [31] However, the capacity of the liver to grow *rapidly* after portal vein rerouting without tissue removal was discovered by chance in 2007, when PVL was combined with an *in-situ-split* of the liver parenchyma by Hans Schlitt in Regensburg, Germany. [32]. Massive volume gain was observed fortuitously on a CT scan one week after the procedure that had been planned as an extended liver resection, but was aborted due a small FLR. The rapid growth, then, made the resection possible. In 2012, Schnitzbauer et al. [28] published a prospective series about the *in-situ-split* hepatectomy approach with an impressive percent hypertrophy of 74% (range: 21-192%) and a curative resection in all patients after a median of 9 days (range: 5-28 days). This new two-stage approach was designed for right trisectomies, allowed faster resection and gave hope to expand the limitations of technical resectability in patients with extensive tumour load. Santibañes and Clavien [33] promoted the procedure under the new name of “ALPPS” (Associating Liver Partition and Portal vein ligation for Staged hepatectomy). First reports described an unacceptably high morbidity and mortality risk, but soon modifications of the procedure tried to improve on the early results.

The Scandinavian LIGRO trial from 2018 [26] was the first randomized controlled trial (RCT) comparing ALPPS vs. TSH with PVE/PVL. The trial demonstrated an increased resection rate after ALPPS compared to the conventional techniques (ALPPS: 92% vs. TSH: 57%, p<0.001). A follow-up evaluation also showed oncological superiority of ALPPS, as the higher transection rate in ALPPS translated directly into a significantly better median survival

(ALPPS: 46 months vs. TSH: 26 months, p=0.028). [34] However, LIGRO was criticised because of the high number of patients with insufficient liver growth, failure to achieve surgical resection in the control group, and the high mortality in both group compared to other, retrospective reports. [35] It was argued, that the observed superiority of ALPPS was more or less a result of the weak performance of the control group.

The initial series by Schnitzbauer et al. reported an alarming overall morbidity of 68% and an in-house mortality of 12%, [28] but as the procedure spread through hospitals worldwide, many experienced the high morbidity of the procedure. An early analysis of the ad-hoc worldwide ALPPS registry at the University of Zurich revealed a heterogeneous practices pattern of ALPPS regarding indications, selection of patients and technical modifications. [36] Early adopters of ALPPS reported morbidities (major complications) and 90-day mortalities of 44-75% [37, 38] and 15-48%, [37-40] respectively. The second report of the ALPPS registry [41] revealed age >60 years (odds ratio (OR): 14.3) and hepatobiliary malignancies (OR: 3.1) as independent risk factor for mortality, while complications were less rampant in CRLM. Additionally, despite a sufficient liver volume gain, PHLF (75%) was shown to be the leading cause of mortality (9%) following ALPPS stage 1. [41] The authors assumed an overestimation of liver function by volume in the rapid growing liver that was also demonstrated by preclinical [42, 43] and clinical studies [44] from the Amsterdam group using technetium-99m (^{99m}Tc) mebrofenin hepatobiliary scintigraphy (HBS). In a multicentric series, the median volume augmentation was 2.9 times greater than the increase of function after ALPPS stage 1. [44] However, a recent series from Amsterdam showed that function actually increased more (2.8-fold) than volume in ALPPS (p=0.009), [45] which was in contrast to the previous findings. In any case, liver volume seemed not to be a reliable parameter in the rapidly growing liver and sparked an interest in liver function/volume assessment. The Amsterdam group proposed an uptake ratio of >2.7%/min/m² in HBS-scan as cut-off for safe liver resection. [46] Also, further series confirmed that this cut-off was more reliable than volume to predict PHLF, [45, 47] regardless of histological damage and laboratory liver function parameters. Nevertheless, HBS has never been really established in many HPB-centers, most likely due to specific know-how required and costs incurred by the procedure.

A meta-analysis of retrospective data comparing ALPPS vs. TSH by Moris et al., [48] that was published just before the LIGRO trial, summarized findings of higher resectability and a lower safety profile to ALPPS, while the oncological outcome appeared similar between ALPPS and TSH. Randomized data came out in 2018 as the Scandinavian LIGRO trial, [26]

~~the first randomized controlled trial (RCT) comparing ALPPS vs. TSH with PVE/PVL between the stages. As expected, ALPPS yielded an increased resection rate compared to TSH (ALPPS: 92% vs. TSH: 57%, $p < 0.001$), with comparable, but high, associated morbidity (ALPPS: 43% vs. TSH: 43%, $p = 0.99$) and mortality rates (ALPPS: 9% vs. TSH: 11%, $p = 0.82$). [26] Also, a follow-up evaluation showed oncological superiority of ALPPS. The higher transection rate in ALPPS translated directly into a significantly better median survival (ALPPS: 46 months vs. TSH: 26 months, $p = 0.028$). [34] Despite this, the general skepticism about ALPPS did not subside. [35] LIGRO was criticized because of the high number of patients with insufficient liver growth, failure to achieve liver resection in the control group, and the high mortality in both, control and ALPPS group, compared to other reports. [35] It was argued, that the observed superiority of ALPPS was more or less a result of the weak performance of the control group.~~

~~ALPPS was hailed as a major breakthrough in regenerative liver surgery. [33] After the initial hype, ALPPS turned out to be too complex and dangerous to replace TSH with PVE or PVL. Dragged down by a low safety profile and limited by the concept of a two-stage procedure, it is not a versatile enough strategy in an aging patient population and for primary liver tumours. However, ALPPS demonstrated the advantages of rapid hypertrophy to improve resectability and survival in metastatic liver tumours and paved the way to the concept of *rapid hypertrophy*.~~

4. Limitations of regenerative liver surgery in two stages

The concept of TSH with the addition of regenerative manoeuvres became well-accepted in the treatment for liver metastases when showing a comparable long-term overall and disease-free survival compared to one-stage resection despite a higher tumour load. [24] However, liver volume gain induced by PVE/PVL remained limited and high dropout rates up to 30-43%, mostly due to tumour progression while awaiting sufficient liver growth, remained the Achilles tendon of regenerative liver surgery. [20, 26, 27] For patients that fail to complete TSH, chemotherapy remains the only treatment with an oncological outcome that is worse compared to those completing TSH. [25]

ALPPS was hailed as major breakthrough in regenerative liver surgery, as it sparked the hope to overcome these limitations of PVE/PVL. [33] However, the initial hype around ALPPS masked a considerable downside of the rapidly induced liver regeneration by a two-stage approach that was actually obvious from the very beginning. Already the initial series by Schnitzbauer et al. reported a high morbidity of 68% and in-house mortality of 12%. [28]

but as the procedure spread through hospitals worldwide, many surgeons experienced the high morbidity of the procedure first hand. An early analysis of the ad-hoc worldwide ALPPS registry at the University of Zurich revealed a heterogenous practices pattern of ALPPS regarding indications, selection of patients and technical modifications. [36] Early adopters of ALPPS reported morbidities (major complications) and 90-day mortalities of 44-75% [37, 38] and 15-48%, [37-40] respectively. The second report of the ALPPS registry [41] revealed age >60 years (odds ratio (OR): 14.3) and hepatobiliary malignancies (OR: 3.1) as independent risk factor for mortality and complications in patients with CRLM. Specifically, in the prospective randomized setting of LIGRO morbidity (ALPPS: 43% vs. TSH: 43%, p=0.99) and mortality rates remained high (ALPPS: 9% vs. TSH: 11%, p=0.82). [26]

Since PHLF was identified as the leading cause of postoperative mortality despite a sufficient liver volume gain after ALPPS stage 1, the question was raised if function increases proportionally to volume in the rapidly growing liver. [41] Preclinical [42, 43] and clinical studies [44] from the Amsterdam group using technetium-99m (^{99m}Tc) mebrofenin hepatobiliary scintigraphy (HBS) supported the hypothesis of an immature liver after rapid liver growth. A multicentric study by the Amsterdam group revealed an overestimation of liver function by a factor of 2.9 compared to volume after ALPPS stage 1. [44] However, in contrast to these findings, a more recent series showed that function actually increased more (2.8-fold) than volume in ALPPS (p=0.009). [45] In any case, liver volume increase appeared not to be a reliable indicator of liver function in the rapidly growing liver and sparked a renewed interest in liver function assessment. The Amsterdam group proposed an uptake ratio of >2.7%/min/m² in HBS-scanning as cut-off for safe liver resection. [46] Also, further series confirmed that this cut-off was more reliable than volume to predict PHLF, [45, 47] regardless of histological damage and laboratory liver function parameters. Nevertheless, HBS is not widely available across many HPB centres, most likely due to specific know-how required and costs incurred by the procedure.

In summary, ALPPS was hailed as a major breakthrough in regenerative liver surgery. [33] But after an initial hype, ALPPS turned out to be too complex and dangerous to replace TSH with PVE or PVL. [49-51] Dragged down by a low safety profile and limited by the concept of a two-stage procedure, it is not a versatile enough strategy in an aging patient population and to also be used for primary liver tumours like HCC and cholangiocarcinoma. Nevertheless, ALPPS demonstrated the advantages of rapid hypertrophy to improve resectability and survival in metastatic liver tumours and paved the way to the concept of *rapid hypertrophy*.

45. The ALPPS modifications

Driven by the allure of *rapid hypertrophy*, a variety of modifications were introduced to improve the safety of ALPPS (figure 1).

Surgical severity was reduced by choosing a minimal invasive approach despite the complexity of the operation. After a first laparoscopic case series in 2012, [52] Machado et al. presented a comparative series of open vs. laparoscopic ALPPS (*lap-ALPPS*) in 2016. [53] In this series, which mostly included patients with CRLM (table 1), both ALPPS stages were performed entirely laparoscopically. Major complications (>3A Dindo-Clavien) were significantly reduced in lap-ALPPS (p=0,006), while liver growth was comparable. Although an era bias couldn't be ruled out, the study showed that lap-ALPPS is feasible and safe in patients with CRLM. Further series confirmed the decreased physiological severity of the minimal invasive approach. [54-56] Also, *Robotic-ALPPS* is feasible[57] and was demonstrated in several case series. [56, 58]

Others reduced the surgical trauma during open ALPPS stage 1. Robles et al. [59] proposed a tourniquet parenchymal ligation instead of surgical transection in his tourniquet ALPPS modification, *T-ALPPS*. The liver parenchymal was not transected to prevent collateralization but simply ligated with an umbilical tape. In a first series in 2014, [59] mostly in patients with CRLM, liver growth and postoperative outcome appeared to be similar to ALPPS. Subsequently, in a propensity score matched analysis in patients with CRLM, T-ALPPS was compared to TSH with PVL during stage I (table 1). [60] T-ALPPS resulted in enhanced liver growth, but disappointingly there was no difference in major morbidities (\geq IIIB Dindo-Clavien) and mortality.

Jiao et al. proposed a radio frequency ablation of the liver parenchyma instead of transection or ligation during a laparoscopically performed stage 1 in his *RALPPS* modification (radiofrequency assisted liver partition with portal vein ligation for staged hepatectomy) in 2015. [55] The Hammersmith team even performed an RCT of RALPPS vs. TSH with PVE in the REBIRTH trial (rapid induction of liver regeneration for major hepatectomy). [56] While complications were comparable, more liver growth (p<0.001) and a higher resection rate (p=0.007) in RALPPS was observed, further supporting the concept that rapid hypertrophy increases resectability.

A third modification to prevent collateralization, partial-ALPPS (*p-ALPPS*), [61] proposed to transect only 50% to 80% of the liver parenchyma to maintain the middle hepatic vein to preserve the venous drainage of segment 4. In three comparative series including various tumour entities, [45, 61, 62] p-ALPPS and ALPPS resulted in comparable liver growth (table 1). One series also provided functional data by HBS, [45] showing that function increased significantly more than volume in ALPPS, but not in p-ALPPS. The lower increase in function in p-ALPPS was also observed in two further series, [54, 62] and may be explained by the above-mentioned portal vein collaterals that are not entirely abrogated by the incomplete transection. [29] In two of three series, major complications did not differ (table 1), [45, 61] while in one series p-ALPPS reduced 90-day mortalities compared to ALPPS. [61] In a third series, [62] complete transection was found to have a significant impact on post-operative complications in ALPPS (odds ratio: 15.7, 95%-confidence interval: 1-244, $p=0.049$). The concept of a partial transection was also investigated in tourniquet ALPPS in a small comparative series of T-ALPPS against “*Tp-ALPPS*” (tourniquet partial-ALPPS). [63] Both approaches displayed no significant difference regarding postoperative outcome and hypertrophy (table 1). The combination of a partial transection with an intraoperative PVE, that was called “*mini ALPPS*”, was also presented in a small series. [64] No complication occurred and liver growth induced by mini ALPPS appeared to be similar to ALPPS (table 1).

Other innovators focused on modification of the portal vein re-routing after parenchymal transection. Inspired by a case of tumour infiltration of the right hilum making classic ALPPS impossible, “hybrid ALPPS” (*hALPPS*) was proposed by the Hamburg group. In hALPPS, PVE replaced PVL of ALPPS and was performed on postoperative day 2 after ALPPS stage 1. [65] The results were reported only in a case series and conclusions cannot be drawn (table 1).

According to a report from the ALPPS registry in 2017, [66] modified ALPPS procedures now encompass more than half of all ALPPS procedures performed since 2015. The authors also observe a decrease in complications as the use of modified versions of ALPPS has increased. This, however, may simply reflect changes in patient selection, specifically an increased prevalence of metastatic disease over primary hepatic tumours.

56. *Simultaneous portal and hepatic vein embolization (PVE/HVE)*

In 2016, the Montpellier group described a new modification of portal vein embolization that induced liver regeneration as rapid as ALPPS by simultaneous embolization of the ipsilateral hepatic vein, the *liver venous deprivation* (LVD) [technique](#). [30] PVE of the right portal vein was performed using n-butyl-cyanoacrylate plus iodized oil (NBCA/lipiodol) and simultaneously Vascular Amplatzer Plugs (AVP, Abbott Vascular, formerly St. Jude Medical) were utilized for outflow, i.e. hepatic vein embolization (HVE). Additionally, NBCA/lipiodol was injected with meticulous precision into small hepatic veins proximal to the AVPs to obstruct potential venous collaterals that became visible during the procedure.

One year later, the Montpellier group added embolization of the middle hepatic vein to the embolization of the right hepatic vein to increase the effect and called it *extended LVD* (eLVD). [67] These findings in humans confirmed results of studies from the Chicago Rush group in pigs [68] that demonstrated that simultaneous ligation of both, portal and ipsilateral hepatic vein (“double ligation”), did not – as expected – result in necrosis of the respective part of the liver as the liver remained viable by arterial perfusion alone. Rather, the double ligation completely abrogated the formation of collaterals from the FLR, which are commonly observed in PVE/PVL, presumably due to the lack of venous outflow, and induced rapid hypertrophy of the liver that is comparable, if not higher than to what can be achieved in ALPPS model in pigs. [29, 68] These findings also argued against the *trauma theory* of rapid hypertrophy that presumes that the hypertrophy effect of ALPPS results from the trauma of the parenchymal transection during the in-situ split and the respective increase in inflammatory cytokines like interleukine-6 (IL-6) and tumour necrosis factor alpha (TNF- α) that have known pro-proliferative properties. [69, 70] The finding that abrogation of collaterals accelerates hypertrophy rather supports the hemodynamic theory that the formation of steal collaterals by transection is what blunts the proliferative effect of PVE and PVL. The importance of steal collaterals is further supported by the findings that the interventional abrogation of large collaterals re-establishes volume growth in cases of failed PVE, [71, 72] and that the degree of transection of the parenchyma – and the resulting prevention of collaterals correlates with the degree of hypertrophy in partial ALPPS. [73]

Six [retrospective](#) comparative cohort studies have been published so far to compare simultaneous embolization of the portal and hepatic veins with PVE alone (table 2). [74-79] In one series, simultaneous portal and hepatic vein embolization was compared with ALPPS. [80] Except for the series by the Montpellier group [30, 67, 74, 78] and one series from Bordeaux, [77] all other groups decided to forego the additional liquid embolization of the

venous system, [75, 76, 79] most likely due to the risk of liquid embolization of the pulmonary vein. The Bordeaux group gave their procedure a name different from “LVD” and “eLVD”: “RASPE” (radiological simultaneous portohepatic vein embolization), [77] while using additional liquid embolization in Montpellier style like in the original LVD technique by Guiu et al. [30] Others gave not enough technical details of the procedure to fully understand what they were doing Others, unfortunately, did not provide sufficiently detailed information about their embolization technique. [75, 80] In order to avoid further confusions, the generic term “PVE/HVE” was introduced by us [79, 81] to refer to the simultaneous embolization of the portal and hepatic vein without additional venous liquid embolization.

In none of the PVE/HVE vs. PVE cohorts, there was a difference in complication rates between the embolization procedures (table 2). [74-79] The most frequent complications after PVE/HVE were fever and pain, which are known from PVE as signs of the “post-embolization syndrome”. Concerns about liver necrosis due to the simultaneous occlusion of the hepatic venous in- and outflow remained unfounded. [81] Only a slight elevation of transaminases was observed and histological signs of necrosis were comparable to PVE. [30, 74] Just as described in the pig model of double ligation [68], it appears that arterial blood flow keeps the embolized liver lobe viable and new venous outflow collaterals from the deportalized side to the growing liver allow venous drainage of the embolized lobe.

While a comparison of liver volume growth in the cohorts remains difficult due to the use of different liver growth units and metrics, all series demonstrate an increased liver growth after PVE/HVE over PVE alone (table 2). [74-79] In the largest series so far, the cohort study of the DRAGON collaborative, [79] liver volume gain was investigated in standardized metrics and revealed a kinetic growth rate (KGR) of 3.5% sFLR/week after PVE/HVE vs. 2.5% sFLR/week ($p < 0.001$) after PVE (figure 2A). Since patients obtained volumetric assessment sooner after PVE/HVE in DRAGON, an additional sensitivity analysis was performed with growth metric after a similar waiting time of 17 (PVE/HVE) and 21 days (PVE), respectively (figure 2B). KGR remained higher after PVE/HVE (PVE/HVE: 3.5% sFLR/week vs. PVE: 2.7% sFLR/week, $p = 0.03$). While volumetric and functional measurements were not congruent in ALPPS [44], two series by Guiu et al. provided functional assessment by HBS and revealed a strictly congruent increase of volume and function after PVE/HVE. [67, 78]

Most importantly, the DRAGON collaborative reported that patients undergoing PVE/HVE had a higher chance to achieve curative liver resection ($p = 0.007$) while time to

resection was not different between PVE/HVE and PVE (PVE/HVE: 37 days (IQR 21-52) vs. PVE: 41 days (IQR 28-61), $p=0.132$). [79]

~~No study found a difference in complications after liver resection between PVE/HVE and PVE so far (table 2). [74-79] The incidence of PHLF after PVE/HVE was comparable, and both, 30- and 90-day mortality, were comparable. Currently, there is no evidence that PVE/HVE is not safe in hepatobiliary malignancies.~~

Recently, a cohort study evaluated PVE/HVE against ALPPS. [80] While percent hypertrophy was comparable, KGR was greater after ALPPS (PVE/HVE: KGR: 2% FLR/day (range 0, 11) vs. ALPPS: 7% FLR/day (range -1, 27), $p<0.001$). This volumetric assessment, however, is biased since it was performed 8 days (range 1, 43) after ALPPS and 28 days (range 4, 52) after PVE/HVE ($p<0.001$), which does not allow to evaluate KGR where time is in the denominator. Resectability in PVE/HVE was lower (PVE/HVE: 73% vs. ALPPS: 91%, $p<0.001$). No differences were seen in terms of postoperative complications and 90-day mortality. However, in PVE/HVE surgery was performed later, patients were older ($p=0.02$) and there were more hepatobiliary malignancies ($p<0.001$) compared to ALPPS.

7. What are the alternatives to regenerative liver surgery?

7.1 Parenchymal sparing surgery (PSS)

Resection of tumour lesions in a parenchymal sparing fashion (parenchymal sparing surgery, PSS), however, allows the removal of multiple tumour lesions without the need of an extended liver resection. [82] The Humanitas group in Milan developed the intraoperative ultrasonography (IOUS) criteria as guideline for the necessity of the resection of tumour infiltrated portal venous structures and the respective liver parenchyma. When 1) the tumour is separated by a thin layer of parenchyma, 2) the vessel wall shows no discontinuation and 3) the tumour surrounds less than 1/3 of the vessel diameter the tumour should be resected by preserving the portal venous structures and corresponding liver parenchyma, even if a positive histological resection margin is expected. Additionally, IOUS allows the detection of hepatic vein collaterals which enable the preservation of liver parenchyma despite the resection of the respective hepatic vein. PSS was compared to TSH in a retrospective comparative series of patients with CRLM and oligometastases. [83] While blood loss and major complication were less in PSS, complete histological tumour resection (R0) was the same between both approaches. The overall survival was also comparable between both approaches, but patients

that failed to achieve the second stage in the TSH group (40%) were not included in the survival analyses.

Despite the need to evaluate every case of a planned TSH for a parenchymal sparing option and the necessity to remind even technically adept and experienced liver surgeons that parenchymal sparing resections can replace a planned TSH, there are two compelling reasons why PSS is not an option: First, when lesions are not just abutting but have a more than 180° involvement of the right or the left inflow pedicle or the three outflow veins and anatomic resection have to be performed: Chemotherapy can sometimes effect a secondary detachment of metastases from vessels due to intrinsic proliferation of liver tissue that may push itself between a lesion that is shrinking due to chemotherapy and the respective vessel. This phenomenon of chemotherapy induced tumour detachment, unique to the liver, is generally not observed in other parenchymal organs and rarely with tumours that have more than 180° vessel involvement. A second reason why PSS may not be an option is diffuse involvement of one liver lobe that cannot be targeted with PSS, because lesions are too close to each other, too multiple and too deep to be resected in cluster resections.

Due to these very different anatomic scenarios that lead experienced surgeons to choose one approach over the other a comparative or even randomized trial will likely not be possible: Situations in which both, PSS and TSH, are possible and equally helpful are very rare. An unbiased comparison therefore is impossible and a randomization ethically not defensible.

7.2 Locoregional heat ablation

In order to avoid the need of a two-stage procedure with the risk of tumour progression while awaiting sufficient liver growth, the MD Anderson group retrospectively evaluated one-stage resection + ablation against classic TSH in patients with CRLM. [84] The study revealed an increased major complication rate (resection + ablation: 20% vs. TSH: 6%, p<.001) and worse 5-year overall survival rate following one-stage resection + ablation (resection + ablation: 24% vs. TSH: 35%, p=.016). Inversely, the Paul Brousse group implemented ablation in the concept of one- and two-stage resections in CRLM when the FLR was affected by tumour lesions and showed in a retrospective study comparable postoperative (Dindo-Clavien >III: resection + ablation: 22% vs. resection alone: 19%, p=.66) and long-term outcomes (5-year survival rate: resection + ablation: 58 month vs. resection alone: 56 month, p=.57) compared to patients undergoing one- and two-stage resections without ablation. [85]

There are some prospective randomised trials comparing resection against ablative procedures in HCC, [86-88] however, the results are partially controversial. According to the Barcelona Clinic Liver Cancer (BCLC) criteria, ablation should be considered in the very early (single lesion with less than 2 cm in size and preserved liver function) and early stage (maximum of 3 lesions with a maximum of 3cms in size and preserved liver function) when patients are not suitable for surgery. [89] Ablation as a fall-back for patients who are not candidates for surgery is non-controversial.

8. What is the role of preoperative chemotherapy?

Only 10-20% of patients with CRLM are primarily resectable. [90] In the remaining patients, secondary resectability can eventually be achieved through chemotherapy by downsizing the tumour, detaching tumours from vascular structures and the FLR. However, “conversion -type” preoperative chemotherapy has to be limited, because liver metastasis with a complete remission (no longer radiologically detectable) reappear in 80% after chemotherapy is stopped or becomes ineffective. [91] Conversion chemotherapies for CRLM have been tested in the randomised CELIM [92] (FOLFOX + cetuximab vs. FOLFIRI + cetuximab) and OLIVIA [93] (FOLFOXIRI + bevacizumab vs. FOLFOX + bevacizumab) trial accomplishing a complete tumour resection (R0) in 33% and 49% (FOLFOX + bevacizumab), respectively. Of course, survival rates in patients requiring conversion chemotherapy are worse than in patients that are primarily resectable, but better than in patients receiving chemotherapy alone. [94]

A recent RCT compared resection + adjuvant chemotherapy (mFOLFOX6) vs. resection and showed that the addition of chemotherapy improves DFS, but not survival. However, it should be noted that in both groups, patients had a low tumour burden with a maximum of 3 liver metastasis and were therefore not representative for patients with the need for regenerative liver surgery. [95] It is highly unlikely that the conclusions of this trial can be applied to scenarios of initial un- or borderline resectability. In contrast, it is likely that methods like PVE/HVE that reduce the surgical severity of liver metastasis removal, but induce fast hypertrophy are advantageous compared to two-stage approaches because they allow patients to remain on chemotherapy until their extensive tumour load is removed. Embolizations can be performed while patients are under chemotherapy and in many cases of PVE/HVE only one surgical resection may be necessary.

Two RCTs are available in patients with unresectable bile tract cancers that suggest a moderate conversion rate after chemotherapy. The first series comparing gemcitabine + cisplatin vs. gemcitabine alone provided a conversion rate of approximately 20% for both regimes. [96] In the second trial, nab-paclitaxel was additionally given to gemcitabine + cisplatin resulting in a comparable conversion rate of 20%. [97] Both trials did not provide further information about the outcome of patients who ultimately underwent surgery and how they were resected.

Whether HCC can be effectively downsized and converted to resectability with the current first line treatment Atezolizumab-Bevacizumab, Lenvatinib and Nivolumab has remains unclear, but data on this are expected in the near future.

9. Conclusion – What is the gold standard of regenerative liver surgery?

In summary, based on long experience and established safety, PVE remains the gold standard of regenerative liver surgery. However, because of limited hypertrophy and therefore resectability, this gold standard will be challenged. ALPPS failed to convince, largely because it is a regenerative strategy tied to a two-stage hepatectomy. PVE/HVE, however, is not tied to two stages of surgery and induces rapid liver growth with a safety profile similar to PVE but with the feasibility of ALPPS. The question if ALPPS or PVE/HVE should replace PVE as the gold standard of regenerative liver surgery has to be answered in multicentre RCTs, two are currently underway (DRAGON international: NCT04272931, LVD France: NCT03995459).

References

1. de Ridder, J., et al., *Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients*. *Oncotarget*, 2016. **7**(34): p. 55368-55376.
2. Sung, H., et al., *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. *CA Cancer J Clin*, 2021. **71**(3): p. 209-249.
3. Hugen, N., et al., *Metastatic pattern in colorectal cancer is strongly influenced by histological subtype*. *Ann Oncol*, 2014. **25**(3): p. 651-657.
4. Benson, A.B., et al., *Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology*. *J Natl Compr Canc Netw*, 2021. **19**(5): p. 541-565.
5. Benson, A.B., et al., *NCCN Guidelines Insights: Rectal Cancer, Version 6.2020*. *J Natl Compr Canc Netw*, 2020. **18**(7): p. 806-815.
6. Jarnagin, W.R., et al., *Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade*. *Ann Surg*, 2002. **236**(4): p. 397-406; discussion 406-7.
7. Kishi, Y., et al., *Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry*. *Ann Surg*, 2009. **250**(4): p. 540-8.
8. Vauthey, J.N., et al., *Body surface area and body weight predict total liver volume in Western adults*. *Liver Transpl*, 2002. **8**(3): p. 233-40.
9. Vauthey, J.N., et al., *Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations*. *Surgery*, 2000. **127**(5): p. 512-9.
10. Shindoh, J., et al., *Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases*. *Ann Surg Oncol*, 2013. **20**(8): p. 2493-500.
11. Truty, M.J. and J.N. Vauthey, *Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma*. *Semin Oncol*, 2010. **37**(2): p. 102-9.
12. Madoff, D.C., et al., *Improving the Safety of Major Resection for Hepatobiliary Malignancy: Portal Vein Embolization and Recent Innovations in Liver Regeneration Strategies*. *Curr Oncol Rep*, 2020. **22**(6): p. 59.
13. Rous, P. and L.D. Larimore, *Relation of the Portal Blood to Liver Maintenance : A Demonstration of Liver Atrophy Conditional on Compensation*. *J Exp Med*, 1920. **31**(5): p. 609-32.
14. Makuuchi M, Takayasu K, Takuma T et al (1984) Preoperative transcatheter embolization of the portal venous branch for patients receiving extended lobectomy due to the bile duct carcinoma. *J Jpn Soc Clin Surg* 45:14–21
15. Azoulay, D., et al., *Right portal vein embolization in preparation for major hepatic resection*. *J Am Coll Surg*, 1995. **181**(3): p. 266-9.
16. Adam, R., et al., *Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors*. *Ann Surg*, 2000. **232**(6): p. 777-85.
17. Imai, K., R. Adam, and H. Baba, *How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective*. *Ann Gastroenterol Surg*, 2019. **3**(5): p. 476-486.
18. Kianmanesh, R., et al., *Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases*. *J Am Coll Surg*, 2003. **197**(1): p. 164-70.
19. Jaeck, D., et al., *A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and*

- bilobar colorectal liver metastases*. *Ann Surg*, 2004. **240**(6): p. 1037-49; discussion 1049-51.
20. Aussilhou, B., et al., *Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant*. *J Gastrointest Surg*, 2008. **12**(2): p. 297-303.
 21. Isfordink, C.J., et al., *Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis*. *Surg Oncol*, 2017. **26**(3): p. 257-267.
 22. Kishi, Y., et al., *Is embolization of segment 4 portal veins before extended right hepatectomy justified?* *Surgery*, 2008. **144**(5): p. 744-51.
 23. Luz, J.H.M., et al., *BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer-A Randomized Controlled Trial Comparing Portal Vein Embolization with N-Butyl-Cyanoacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils*. *Radiology*, 2021. **299**(3): p. 715-724.
 24. Imai, K., et al., *Potential of a cure in patients with colorectal liver metastases and concomitant extrahepatic disease*. *J Surg Oncol*, 2017. **115**(4): p. 488-496.
 25. Brouquet, A., et al., *High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome*. *J Clin Oncol*, 2011. **29**(8): p. 1083-90.
 26. Sandstrom, P., et al., *ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)*. *Ann Surg*, 2018. **267**(5): p. 833-840.
 27. van Lienden, K.P., et al., *Portal vein embolization before liver resection: a systematic review*. *Cardiovasc Intervent Radiol*, 2013. **36**(1): p. 25-34.
 28. Schnitzbauer, A.A., et al., *Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings*. *Ann Surg*, 2012. **255**(3): p. 405-14.
 29. Deal, R., et al., *Rapid Liver Hypertrophy After Portal Vein Occlusion Correlates with the Degree of Collateralization Between Lobes-a Study in Pigs*. *J Gastrointest Surg*, 2018. **22**(2): p. 203-213.
 30. Guiu, B., et al., *Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique*. *Eur Radiol*, 2016. **26**(12): p. 4259-4267.
 31. Nadalin, S., et al., *Volumetric and functional recovery of the liver after right hepatectomy for living donation*. *Liver Transpl*, 2004. **10**(8): p. 1024-9.
 32. Schlitt, H.J., C. Hackl, and S.A. Lang, *'In-Situ Split' Liver Resection/ALPPS - Historical Development and Current Practice*. *Visc Med*, 2017. **33**(6): p. 408-412.
 33. de Santibanes, E. and P.A. Clavien, *Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach*. *Ann Surg*, 2012. **255**(3): p. 415-7.
 34. Hasselgren, K., et al., *ALPPS Improves Survival Compared With TSH in Patients Affected of CRLM: Survival Analysis From the Randomized Controlled Trial LIGRO*. *Ann Surg*, 2019.
 35. Allard, M.A., et al., *Comments on: "ALPPS Improves Survival Compared With TSH in Patients Affected of CRLM: Survival Analysis From the Randomized Controlled Trial LIGRO" Survival Benefit of ALPPS versus TSH: a Proof of Concept or a Concept to be Proved?* *Ann Surg*, 2020.
 36. Buac, S., et al., *The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry*. *HPB (Oxford)*, 2016. **18**(5): p. 442-8.

37. Olthof, P.B., et al., *High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry*. HPB (Oxford), 2017. **19**(5): p. 381-387.
38. Serenari, M., et al., *Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014*. HPB (Oxford), 2016. **18**(5): p. 419-27.
39. Schadde, E., et al., *ALPPS Offers a Better Chance of Complete Resection in Patients with Primarily Unresectable Liver Tumors. Results of a Multicentre Analysis: Reply*. World J Surg, 2015. **39**(7): p. 1850-1.
40. Nadalin, S., et al., *Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Lessons Learned from 15 cases at a single centre*. Z Gastroenterol, 2014. **52**(1): p. 35-42.
41. Schadde, E., et al., *Prediction of Mortality After ALPPS Stage-I: An Analysis of 320 Patients From the International ALPPS Registry*. Ann Surg, 2015. **262**(5): p. 780-5; discussion 785-6.
42. Olthof, P.B., et al., *Comparable liver function and volume increase after portal vein embolization in rabbits and humans*. Surgery, 2017. **161**(3): p. 658-665.
43. Olthof, P.B., et al., *Hepatic parenchymal transection increases liver volume but not function after portal vein embolization in rabbits*. Surgery, 2017. **162**(4): p. 732-741.
44. Olthof, P.B., et al., *Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function*. Surgery, 2017. **162**(4): p. 775-783.
45. Rassam, F., et al., *Comparison of functional and volumetric increase of the future remnant liver and postoperative outcomes after portal vein embolization and complete or partial associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)*. Ann Transl Med, 2020. **8**(7): p. 436.
46. de Graaf, W., et al., *Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection*. J Gastrointest Surg, 2010. **14**(2): p. 369-78.
47. Tomassini, F., et al., *Hepatobiliary scintigraphy and kinetic growth rate predict liver failure after ALPPS: a multi-institutional study*. HPB (Oxford), 2020. **22**(10): p. 1420-1428.
48. Moris, D., et al., *Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis*. World J Surg, 2018. **42**(3): p. 806-815.
49. Olthof, P.B., A.A. Schnitzbauer, and E. Schadde, *The HPB controversy of the decade: 2007-2017 - Ten years of ALPPS*. Eur J Surg Oncol, 2018. **44**(10): p. 1624-1627.
50. Belghiti, J., S. Dokmak, and E. Schadde, *ALPPS: Innovation for innovation's sake*. Surgery, 2016. **159**(5): p. 1287-8.
51. Olthof, P.B. and E. Schadde, *The rush to novelty and high expectations in surgery: the case of ALPPS*. J Clin Transl Res, 2016. **2**(3): p. 79-83.
52. Machado, M.A., F.F. Makdissi, and R.C. Surjan, *Totally laparoscopic ALPPS is feasible and may be worthwhile*. Ann Surg, 2012. **256**(3): p. e13; author reply e16-9.
53. Machado, M.A., et al., *Transition from open to laparoscopic ALPPS for patients with very small FLR: the initial experience*. HPB (Oxford), 2017. **19**(1): p. 59-66.
54. Truant, S., et al., *Laparoscopic Partial ALPPS: Much Better Than ALPPS!* Ann Hepatol, 2019. **18**(1): p. 269-273.
55. Gall, T.M., et al., *Radio-frequency-assisted Liver Partition with Portal vein ligation (RALPP) for liver regeneration*. Ann Surg, 2015. **261**(2): p. e45-6.

56. Jiao, L.R., et al., *Rapid Induction of Liver Regeneration for Major Hepatectomy (REBIRTH): A Randomized Controlled Trial of Portal Vein Embolisation versus ALPPS Assisted with Radiofrequency*. *Cancers (Basel)*, 2019. **11**(3).
57. Vicente, E., et al., *First ALPPS procedure using a total robotic approach*. *Surg Oncol*, 2016. **25**(4): p. 457.
58. Machado, M.A.C., R.C. Surjan, and F. Makdissi, *Robotic ALPPS*. *Ann Surg Oncol*, 2020. **27**(4): p. 1174-1179.
59. Robles, R., et al., *Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure*. *Br J Surg*, 2014. **101**(9): p. 1129-34; discussion 1134.
60. Robles-Campos, R., et al., *Long-Term Outcome After Conventional Two-Stage Hepatectomy Versus Tourniquet-ALPPS in Colorectal Liver Metastases: A Propensity Score Matching Analysis*. *World J Surg*, 2019. **43**(9): p. 2281-2289.
61. Petrowsky, H., et al., *Is partial-ALPPS safer than ALPPS? A single-center experience*. *Ann Surg*, 2015. **261**(4): p. e90-2.
62. Alvarez, F.A., et al., *Associating liver partition and portal vein ligation for staged hepatectomy offers high oncological feasibility with adequate patient safety: a prospective study at a single center*. *Ann Surg*, 2015. **261**(4): p. 723-32.
63. Robles-Campos, R., et al., *A New Surgical Technique Variant of Partial ALPPS (Tourniquet Partial-ALPPS)*. *Ann Surg*, 2021. **273**(1): p. e22-e24.
64. de Santibanes, E., et al., *Inverting the ALPPS paradigm by minimizing first stage impact: the Mini-ALPPS technique*. *Langenbecks Arch Surg*, 2016. **401**(4): p. 557-63.
65. Li, J., et al., *Avoid "All-Touch" by Hybrid ALPPS to Achieve Oncological Efficacy*. *Ann Surg*, 2016. **263**(1): p. e6-7.
66. Linecker, M., et al., *Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity*. *Ann Surg*, 2017. **266**(5): p. 779-786.
67. Guiu, B., et al., *Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function*. *Eur Radiol*, 2017. **27**(8): p. 3343-3352.
68. Schadde, E., et al., *Simultaneous hepatic and portal vein ligation induces rapid liver hypertrophy: A study in pigs*. *Surgery*, 2019. **165**(3): p. 525-533.
69. Schlegel, A., et al., *ALPPS: from human to mice highlighting accelerated and novel mechanisms of liver regeneration*. *Ann Surg*, 2014. **260**(5): p. 839-46; discussion 846-7.
70. Shi, H., et al., *A preliminary study of ALPPS procedure in a rat model*. *Sci Rep*, 2015. **5**: p. 17567.
71. Denys, A.L., et al., *Failure of right portal vein ligation to induce left lobe hypertrophy due to intrahepatic portoportal collaterals: successful treatment with portal vein embolization*. *AJR Am J Roentgenol*, 1999. **173**(3): p. 633-5.
72. van Lienden, K.P., et al., *Intrahepatic left to right portoportal venous collateral vascular formation in patients undergoing right portal vein ligation*. *Cardiovasc Intervent Radiol*, 2013. **36**(6): p. 1572-1579.
73. Chan, A.C.Y., et al., *Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS*. *Surgery*, 2017. **161**(2): p. 357-364.
74. Panaro, F., et al., *Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center*. *Hepatobiliary Surg Nutr*, 2019. **8**(4): p. 329-337.

75. Kobayashi, K., et al., *Liver venous deprivation compared to portal vein embolization to induce hypertrophy of the future liver remnant before major hepatectomy: A single center experience*. *Surgery*, 2020.
76. Le Roy, B., et al., *Combined biembolization induces higher hypertrophy than portal vein embolization before major liver resection*. *HPB (Oxford)*, 2020. **22**(2): p. 298-305.
77. Laurent, C., et al., *Radiological Simultaneous Portohepatic Vein Embolization (RASPE) Before Major Hepatectomy: A Better Way to Optimize Liver Hypertrophy Compared to Portal Vein Embolization*. *Ann Surg*, 2020. **272**(2): p. 199-205.
78. Guiu, B., et al., *Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes*. *Hepatobiliary Surg Nutr*, 2020. **9**(5): p. 564-576.
79. Heil, J., et al., *Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis*. *Br J Surg*, 2021. **108**(7): p. 834-842.
80. Chebaro, A., et al., *Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy?: A Retrospective Multicentric Study*. *Ann Surg*, 2021. **274**(5): p. 874-880.
81. Heil, J. and E. Schadde, *Simultaneous portal and hepatic vein embolization before major liver resection*. *Langenbecks Arch Surg*, 2021. **406**(5): p. 1295-1305.
82. Torzilli, G., et al., *One-stage ultrasonographically guided hepatectomy for multiple bilobar colorectal metastases: a feasible and effective alternative to the 2-stage approach*. *Surgery*, 2009. **146**(1): p. 60-71.
83. Torzilli, G., et al., *Is Enhanced One-Stage Hepatectomy a Safe and Feasible Alternative to the Two-Stage Hepatectomy in the Setting of Multiple Bilobar Colorectal Liver Metastases? A Comparative Analysis between Two Pioneering Centers*. *Dig Surg*, 2018. **35**(4): p. 323-332.
84. Mizuno, T., et al., *Two-Stage Hepatectomy vs One-Stage Major Hepatectomy with Contralateral Resection or Ablation for Advanced Bilobar Colorectal Liver Metastases*. *J Am Coll Surg*, 2018. **226**(5): p. 825-834.
85. Imai, K., et al., *Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases*. *Br J Surg*, 2017. **104**(5): p. 570-579.
86. Chen, M.S., et al., *A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma*. *Ann Surg*, 2006. **243**(3): p. 321-8.
87. Huang, J., et al., *A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria*. *Ann Surg*, 2010. **252**(6): p. 903-12.
88. Feng, K., et al., *A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma*. *J Hepatol*, 2012. **57**(4): p. 794-802.
89. Reig, M., et al., *BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update*. *J Hepatol*, 2022. **76**(3): p. 681-693.
90. Van Cutsem, E., et al., *ESMO consensus guidelines for the management of patients with metastatic colorectal cancer*. *Ann Oncol*, 2016. **27**(8): p. 1386-422.
91. Passot, G. and J.N. Vauthey, *In favor of two-stage hepatectomy (TSH)*. *Eur J Surg Oncol*, 2015. **41**(12): p. 1566-7.
92. Folprecht, G., et al., *Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial*. *Lancet Oncol*, 2010. **11**(1): p. 38-47.

93. Gruenberger, T., et al., *Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial*. *Ann Oncol*, 2015. **26**(4): p. 702-708.
94. Adam, R., et al., *Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival*. *Ann Surg*, 2004. **240**(4): p. 644-57; discussion 657-8.
95. Kanemitsu, Y., et al., *Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial*. *J Clin Oncol*, 2021. **39**(34): p. 3789-3799.
96. Valle, J., et al., *Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer*. *N Engl J Med*, 2010. **362**(14): p. 1273-81.
97. Shroff, R.T., et al., *Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial*. *JAMA Oncol*, 2019. **5**(6): p. 824-830.

Tables:

Table 1: ALPPS modifications

Author/Year	Acronym	n	Tumor type	Time between the stages (day)	Hyper-trophy	Feasibility of resection	Complications (Dindo-Clavien)	Posthepatectomy liver failure
Machado et al. 2017 [56]	lap-ALPPS	ALPPS: 20 vs. lap-ALPPS: 10	ALPPS: CRLM: 17 Other: 3 vs. lap-ALPPS: CRLM: 9 Other: 1	ALPPS: 21 (11-38) vs. lap-ALPPS: 21 (9-30)	ALPPS: 152% (56-215) vs. lap-ALPPS: 118% (42-157)	ALPPS: 18/20 (90%) vs. 10/10 (100%)	>IIIA.* ALPPS: 10/20 (50%) vs. lap-ALPPS: 0/10	ISGLS.* ALPPS: 8 (44%) vs. lap-ALPPS: 0/10
Robles et al. 2019 [63]	T-ALPPS	TSH: 21 vs. T-ALPPS: 21	TSH: CRLM: 21 vs. CRLM: 21	TSH: 45 (28-60) vs. T-ALPPS: 15 (9-31)	TSH: 39% (21-66) vs. T-ALPPS: 68% (22-100)	TSH: 19/21 (91%) vs. T-ALPPS: 21/21 (100%)	≥IIIB.# TSH: 3/19 (16%) vs. T-ALPPS: 2/21 (10%)	≥IIIB.# TSH: 2/19 (11%) vs. T-ALPPS: 2/21 (10%)
Jiao et al. 2019 [59]	RALPPS	TSH: 24 vs. RALPPS: 26	TSH: CRLM: 19 Other: 5 vs. RALPPS: CRLM: 20 Other: 6	TSH: 35 (21-75) vs. RALPPS: 20 (SD 14-36)	TSH: 18% (±10%) vs. RALPPS: 81% (±14%)	TSH: 16/24 (67%) vs. RALPPS: 24/26 (92%)	≥IIIA.# TSH: 1/16 (6%) vs. RALPPS: 5/24 (21%)	n.r.
Petrowsky et al. 2015 [64]	p-ALPPS	ALPPS: 18 vs. p-ALPPS: 6	CRLM: 16 Other: 8	ALPPS: 9 (range 7-69) vs. p-ALPPS: 11 (range 7-21)	ALPPS: 61% vs. p-ALPPS: 60%	ALPPS: 18/18 (100%) vs. p-ALPPS: 6/6 (100%)	≥IIIB.# ALPPS: 6/18 (33%) vs. p-ALPPS: 2/6 (33%)	n.r.
Alvarez et al. 2015 [53]	p-ALPPS	ALPPS: 9 vs. p-ALPPS: 21	CRLM: 19 Other: 11	ALPPS and p-ALPPS: 6 (range 4-67)	ALPPS: 107% (SD ±12) vs. p-ALPPS: 90% (SD ±21)	ALPPS and p-ALPPS: 29/30 (97%)	≥IIIA.# ALPPS and p-ALPPS: 10/29 (36%)	ISGLS.# ALPPS and p-ALPPS: 2/29 (7%)
Rassam et al. 2020 [43]	p-ALPPS	ALPPS: 12 vs. p-ALPPS: 9	ALPPS: CRLM: 11 Other: 1 vs. p-ALPPS: CRLM: 6 Other: 3	ALPPS: 15 (IQR 10-19) vs. p-ALPPS: 17 (IQR 14-42)	n.r.	ALPPS: 10/12 (83%) vs. p-ALPPS: 6/9 (67%)	≥IIIA.# ALPPS: 3/10 (30%) vs. p-ALPPS: 1/6 (17%)	ISGLS.# ALPPS: 2/10 (20%) vs. p-ALPPS: 0/6
Robles-Campos et al. 2021 [65]	Tp-ALPPS	T-ALPPS: 6 vs. Tp-ALPPS: 6	T-ALPPS: CRLM: 6 vs. Tp-ALPPS: CRLM: 6	n.r.	T-ALPPS: 68% (SD 40-97) vs. Tp-ALPPS: 69% (SD 39-99)	T-ALPPS: 6/6 (100%) vs. Tp-ALPPS: 6/6 (100%)	≥IIIB.# T-ALPPS: 1/6 (17%) vs. Tp-ALPPS: 0/6	ISGLS.# T-ALPPS: 2/6 (33%) vs. Tp-ALPPS: 0/6
Santibañes et al. 2016 [66]	Mini-ALPPS	4	CRLM: 3 Other: 1	n.r.	61% (range 49-79)	4/4 (100%)	≥IIIA.# 0/4	ISGLS.# 0/4
Li et al. 2016 [67]	hALPPS	2	GB: 2	case 1: 10 case 2: 15	case 1: 85% case 2: 66%	2/2 (100%)	≥IIIA.# 1/2 (50%)	ISGLS.# 0/2

* in both stages; # post stage 2
ALPPS: associating liver partition and portal vein ligation for staged hepatectomy; CRLM: colorectal liver metastasis; GB: gallbladder cancer; hALPPS: hybrid ALPPS; ISGLS: international study group of liver surgery; lap-ALPPS: laparoscopic-ALPPS; p-ALPPS: partial-ALPPS; RALPPS: radiofrequency assisted liver partition with portal vein ligation for staged hepatectomy; TSH: two-stage hepatectomy; T-ALPPS: Tourniquet-ALPPS; Tp-ALPPS: Tourniquet partial-ALPPS

Table 2: Comparative series about PVE/HVE

Author/Year	Study design	n	Age (PVE/HVE)	Type of tumor (PVE/HVE)	Peri-interventional complications (Dindo-Clavien) (PVE/HVE vs. PVE)	Intervention to first imaging (days) (PVE/HVE vs. PVE)	Percent hypertrophy (PVE/HVE vs. PVE)	Kinetic growth rate (KGR) (PVE/HVE vs. PVE)	Resection rate (PVE/HVE vs. PVE)	Post-operative Complications (Dindo-Clavien) (PVE/HVE vs. PVE)	Post-hepatectomy liver failure (PVE/HVE vs. PVE)
Panaro et al. 2019 [76]	comparative series	PVE/HVE: 13 PVE: 16	n.r.	CRLM: 10 HCC: 3	0 vs. 0	21 vs. 21	n.r.	16 cc/day (SD ±7) vs. 5 cc/day (SD ±4)	13/13 (100%) vs. 15/16 (94%)	Major ≥IIIa: 1/13 (8%) vs. 3/15 (20%)	3/13 (23%) vs. 2/15 (13%)
Kobayashi et al. 2020 [77]	comparative series	PVE/HVE: 21 PVE: 39	65 (range 25-85)	CRLM: 10 HCC: 2 PHCC: 8	Minor: 1/21 (5%) vs. Minor: 0	22 (IQR 17-30) vs. 26 (IQR 20-33)	35% (IQR 23-54%) vs. 24% (IQR 7-40%)	2.9% FLR/week (IQR 1.9-4.3) vs. 1.4% FLR/week (IQR 0.7-2.1)	20/21 (95%) vs. 30/39 (77%)	Major >III: 7/20 (35%) vs. 11/30 (37%)	n.r.
Le Roy et al. 2020 [78]	comparative series	PVE/HVE: 31 PVE: 41	65 (CI 55-70)	CRLM: 18 HCC: 5 IHCC: 2 PHCC: 5 Other: 1	0 vs. 0	26 vs. 27	51.2% (SD ±41.7%) vs. 31.9% (SD ±34%)	19% FLR/week (SD ±18) vs. 8% FLR/week (SD ±13)	25/31 (81%) vs. 31/41 (76%)	Major >IIIa: 5/25 (20%) vs. 3/31 (10%)	n.r.
Laurent et al. 2020 [79]	comparative series	PVE/HVE: 37 PVE: 36	64 (IQR 61-71)	CRLM:23 IHCC: 7 HCC: 4 NET: 2	Minor: 37/37 (100%) vs. Minor: 34/36 (94%)	31 (IQR 21-40) vs. 30 (IQR 25-43)	61% (range 18-201) vs. 29% (range 9-61)	n.r.	32/37 (86%) vs. 32/36 (89%)	Major ≥IIIa: 6/32 (19%) vs. 10/32 (31%)	ISGLS: 0/32 vs. 7/32 (22%)
Guiu et al. 2020 [80]	comparative series	PVE/HVE: 29 PVE: 22	62 (IQR 26-79)	Metastases: 22 IHCC: 4 HCC: 2 Other: 1	Minor: 6/29 (21%) vs. Minor 3/22 (14%)	21 vs. 21	53% (min – max: 1-176) vs. 19% (min – max: 11 – 102)	n.r.	21/22 (96%) vs. 27/29 (93%)	Major ≥IIIa: 3/21 (14%) vs. 3/27 (11%)	50-50 criteria: 0/21 vs. 0/27
Heil et al. 2021 [81]	comparative series	PVE/HVE: 39 PVE: 160	63 (IQR 52-67)	CRLM: 19 HCC: 4 IHCC: 4 PHCC: 5 GBC: 4 Other: 3	Minor: 5/39 (13%) Major: 1/39 (3%) vs. Minor: 22/160 (14%) Major: 3/160 (2%)	17 (IQR 13-32) vs. 24 (IQR 19-37)	59% (IQR 45-79) vs. 48% (IQR 24-69)	3.5% sFLR/week (IQR 2.2-7.1) vs. 2.5% sFLR/week (IQR 1.1-3.8)	35/39 (90%) vs. 109/160 (68%)	Major >IIIa: 9/35 (26%) vs. 37/109 (34%)	ISGLS: 4/35 (11%) vs. 27/109 (25%)

cc: cubic centime; CI: confidence interval; CRLM: colorectal liver metastasis; HCC: hepatocellular carcinoma, FLR: future liver remnant; IHCC: intrahepatic cholangiocellular carcinoma; ISGLS: International Study Group of Liver Surgery; NET: neuroendocrine tumor; n.r.: not reported; PHCC: perihilar cholangiocarcinoma; PVE: portal vein embolization; PVE/HVE: simultaneous portal and hepatic vein embolization; SD: standard deviation; sFLR: standardized future liver remnant

Figure legends:

Figure 1: Recent innovations in rapid regenerative liver surgery

Figure 2: Kinetic growth rate

Volume increase in standardized future liver remnant (sFLR) per week for simultaneous portal and hepatic vein embolization (PVE/HVE) and portal vein embolization (PVE) for *all patients* (A) and for *matched subgroups* (B), based on a 1:1 match for the closest time to first imaging, age, Charlson comorbidity index, cirrhosis, diabetes and Bevacizumab.

The colored arrows show *median* liver growth for PVE/HVE (orange) and PVE (grey).

Figure 3: Type of procedures